GTBP (GT Biopharma Inc) רווחיות גולמית

GTBP (GT Biopharma Inc) - סמל מסחרי של החברה

GT Biopharma, Inc. (GTBP) gross margins demonstrate pricing power in hematology due to the inelastic demand for leukemia treatments. The development of TriKE bispecific activators enables the targeted destruction of tumors via the patient's NK cells. The current stage of clinical trials for innovative immunotherapeutic agents confirms the company's strategic direction, while 0.00 serves as the final benchmark for this metric.

GTBP רווחיות גולמית GT Biopharma Corp (04.07.2022 - 20.11.2026)

פילוחי מדדים פיננסיים ומדדי שוק עבור GT Biopharma, Inc. (GTBP)

- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:GT Biopharma, Inc.
דוגמת מוצר של GT Biopharma Corporation

GT Biopharma, Inc. (GTBP) specializes in developing innovative blood cancer immunotherapy methods amidst unstable international supply chains. Gross margin measures the portion of revenue remaining after covering direct production costs, reflecting the efficiency of biomaterial cost management. Analyzing gross profit margins allows investors to assess business resilience to geopolitical risks and avoid purchasing the asset at a valuation peak.